nowoF&FWNYFF
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 241
`
`DEFOREST MCDUFF, Ph.D.
`
`for the declarations in the IPR cases, correct?
`
`A.
`
`Q.
`
`Yes, that's correct.
`
`All right.
`
`Now,
`
`there was a
`
`question or some questions at the start of the
`
`deposition about the contents of your
`
`respective declarations, and so if you have
`
`those with you,
`
`they were Exhibit 1055 which
`
`was
`
`your declaration in the 1622 case and
`
`Exhibit 1055 which was your exhibit in the 1621
`
`case.
`
`
`
`Now,
`
`I believe there was some
`
`testimony about some omissions in the 1621 case
`
`from your declaration.
`
`Can you tell us what
`
`the omissions were?
`
`A.
`
`Yes. As submitted and in the
`
`version in front of me,
`
`there was a chart on
`
`Page 9 that appears to have been omitted for a
`
`printing issue and the attachments from page 26
`
`to page 45 which are present in Exhibit 1055 in
`
`the 1622 case are not present in my declaration
`
`in Exhibit 1055 in the 1621 case. Yet the
`
`attachments are identical to those in the 1622
`
`case.
`
`om
`
`Okay.
`
`So the 1622 case at the
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 241 of 297
`
`

`

`DEFOREST MCDUFF, Ph.D.
`
`end of paragraph 15 has a chart in it; is that
`
`Page 242
`
`right?
`
`A.
`
`Yes.
`
`And that chart is omitted in
`
`the 1621 case?
`
`A.
`
`Q.
`
`In the declaration there, yes.
`
`But it should have been the
`
`identical chart is that correct?
`
`A.
`
`Yes.
`
`MR. DELAFIELD: Objection.
`
`BY MR. MATHAS:
`
`Q.
`
`All right. What chart should
`
`have been there?
`
`MR. DELAFIELD:
`
`Same objection.
`
`BY THE WITNESS:
`
`A.
`
`The same chart that is in the
`
`1622 declaration as well as in the underlying
`
`materials cited in footnote 6 in the 1621
`
`declaration.
`
`BY MR. MATHAS:
`
`Q.
`
`All right. And the exhibits
`
`that were omitted in the 1621 case, how, if at
`
`all, were they different from the exhibits
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`submitted in the 1622 case?
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 242 of 297
`
`

`

`Page 243
`
`DEFOREST MCDUFF, Ph.D.
`
`A.
`
`They were identical.
`
`MR. MATHAS: All right.
`
`Can we
`
`mark this as Exhibit 3, please -- or 4 for the
`
`record, please.
`
`MR. DELAFIELD:
`
`I am going to
`
`object to this exhibit.
`
`MR. MATHAS:
`
`Fine,
`
`I am making a
`
`record.
`
`
`
`(WHEREUPON, a certain document
`
`was marked McDuff Deposition
`
`Exhibit No. 4, for
`
`identification, as of 4/6/18.)
`
`BY MR. MATHAS:
`
`Q.
`
`Dr. McDuff,
`
`the court reporter
`
`has
`
`handed you what's been marked for
`
`identification purposes as McDuff Exhibit 4
`
`which I will represent to you is a corrected
`
`version of Exhibit 1055 that was sent to
`
`counsel for the patent owner last evening.
`
`This has not been filed in the IPR proceeding
`
`as of today.
`
`Would you turn with me,
`
`please,
`
`to page 9 the end of paragraph 15.
`
`Does paragraph 15 in Exhibit 4 that I just
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 243 of 297
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`Page 244
`
`DEFOREST MCDUFF, Ph.D.
`
`handed you correctly show the chart that was
`
`omitted from your original Exhibit 1055 and
`
`1621?
`
`A.
`
`Q.
`
`Yes.
`
`And if you will turn with me
`
`to page 26 through 45 of this Exhibit 4 that I
`
`have handed you, do pages 26 through 45 of
`
`Exhibit 4 correctly reflect the omitted exhibit
`
`from the original Exhibit 1055?
`
`A.
`
`Q.
`
`Yes.
`
`Are you aware of any other
`
`differences between the document I have handed
`
`you as Exhibit 4 and the document that was
`
`filed as Exhibit 1055 in IPR 1621?
`
`A.
`
`No,
`
`I am not.
`
`MR. MATHAS:
`
`I have no further
`
`
`
`questions.
`
`FURTHER EXAMINATION
`
`BY MR. DELAFIELD:
`
`Q.
`
`I have a couple of questions.
`
`So this new declaration that
`
`we received yesterday, do you see at the bottom
`
`it says page 1 of 25?
`
`A.
`
`I do.
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 244 of 297
`
`

`

`Page 245
`
`DEFOREST MCDUFF, Ph.D.
`
`0.
`
`A.
`
`But there's 45 pages, correct?
`
`Yes,
`
`there are 45 pages in the
`
`declaration including the declaration and the
`
`attachments.
`
`Q.
`
`So the page numbering is off
`
`for the first 25 pages with respect to how many
`
`total pages, correct?
`
`Ais
`
`Yes,
`
`I suppose that could say
`
`page 1 of 45, and it would say 45 consistently
`
`throughout as it does in the attachments.
`
`Q.
`
`Ay
`
`Did you --
`
`Either way I think it
`
`represents the full declaration.
`
`Q.
`
`Did you yourself prepare this
`
`replacement declaration?
`
`As
`
`I did not do so personally.
`
`I
`
`did so through discussion and assistance from
`
`counsel.
`
`Q.
`
`And you said you first noticed
`
`the missing exhibits and graph yesterday as
`
`
`
`well?
`
`A.
`
`Yes.
`
`MR. DELAFIELD: Okay.
`
`I have no
`
`further questions.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 245 of 297
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`Page 246
`
`DEFOREST MCDUFF, Ph.D.
`
`MR. MATHAS:
`
`One follow up.
`
`FURTHER EXAMINATION
`
`BY MR. MATHAS:
`
`Q.
`
`Dr. McDuff, do the -- does the
`
`additional information in Exhibit 4 or the
`
`absence of the information in Exhibit 4 change
`
`your opinions with respect to the '240 patent
`
`in case 1621?
`
`As
`
`No,
`
`they are all the same
`
`either way regardless of whether it's the full
`
`document with all of the attachments and chart
`
`or the abridged document that omits those.
`
`MR. MATHAS:
`
`Thank you.
`
`I have no
`
`further questions.
`
`FURTHER EXAMINATION
`
`BY MR. DELAFIELD:
`
`Q.
`
`One question.
`
`You were asked
`
`if the information in Exhibit 4 or the absence
`
`of information of Exhibit 4 would change your
`
`opinions with respect to the '240 patent,
`
`correct?
`
`A.
`
`More or less.
`
`So if your declaration did not
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`then you
`have any of the exhibits or the chart,
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 246 of 297
`
`

`

`Page 247
`
`DEFOREST MCDUFF, Ph.D.
`
`couldn't rely on those in your declaration or
`
`cite them, correct?
`
`MR. MATHAS: Object to the form.
`
`BY THE WITNESS:
`
`A.
`
`I don't agree with that.
`
`The
`
`most relevant charts from my attachments are in
`
`both copies of the declaration.
`
`The charts
`
`themselves are in line in paragraphs 24 and
`
`25
`
`- sorry -- 23 and 24, and the attachments
`
`simply provide the supporting calculations
`
`underlying those charts, but the fundamental
`
`
`
`opinions are the same.
`
`BY MR. DELAFIELD:
`
`Q.
`
`And so without the
`
`attachments,
`
`there would be no supporting
`
`calculations for the '240 declaration, correct?
`
`MR. MATHAS: Object
`
`to the form.
`
`BY THE WITNESS:
`
`A.
`
`There would be no details
`
`underlying how the calculations were performed.
`
`However,
`
`they are described in the declaration
`
`itself.
`
`MR. DELAFIELD: Okay.
`
`I have no
`
`further questions.
`
`&WNHNF
`oaoOWw
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 247 of 297
`
`

`

`Page 248
`
`DEFOREST MCDUFF, Ph.D.
`
`MR. MATHAS:
`
`Thank you, Dr. McDuff.
`
`THE VIDEOGRAPHER:
`
`The time is now
`
`4:18 p.m. This is the end of media 4. This
`
`concludes this deposition. We are off the
`
`record.
`
`(WHEREUPON,
`
`the deposition was
`
`concluded at 4:18 p.m.)
`
`&WNHNF
`oaoOWw
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 248 of 297
`
`

`

`o7awnOFF&FWDYEF
`
`10
`
`11
`
`i2
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`Zi
`
`22
`
`23
`
`24
`
`25
`
`Page 249
`
`STATE OF
`
` _—__—ss—“(:CO”
`
`COUNTY OF
`
`:ss
`
`)
`
`)
`
`I, DEFOREST MCDUFF,
`
`the witness
`
`herein, having read the foregoing
`
`testimony of the pages of this deposition,
`
`do hereby certify it to be a true and
`
`correct transcript, subject to the
`
`corrections, if any,
`
`shown on the attached
`
`page.
`
`DEFOREST MCDUFF
`
`
`
`Sworn and subscribed to before me,
`
`this day of , 2018.
`
`Notary Public
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 249 of 297
`
`

`

`Page 250
`
`CERTIFICATE
`
`OF
`
`CERTIFIED SHORTHAND REPORTER
`
`
`
`I, ANDREA L. KIM, a State of Illinois
`
`Licensed Certified Shorthand Reporter, License
`
`number 84-3722, do hereby certify:
`
`commencement of the examination of the
`
`That previous to the
`
`aforesaid witness,
`
`the witness was duly sworn
`
`or affirmed to testify the whole truth
`
`concerning the matters herein;
`
`That the foregoing deposition
`
`transcript was reported stenographically by me,
`
`was
`
`thereafter reduced to typewriting under my
`
`personal direction and constitutes a true and
`
`accurate record of the testimony given and the
`
`proceedings had at the aforesaid deposition;
`
`That the said deposition was
`
`taken before me at the time and place
`
`specified;
`
`That I am not a relative or
`
`employee or attorney or counsel for any of the
`
`parties herein, nor a relative or employee of
`
`o7aonOFF&FWDYEF
`
`10
`
`Li
`
`12
`
`Lg
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 250 of 297
`
`

`

`Page 251
`
`such attorney or counsel for any of the parties
`
`hereto, nor am I interested directly or
`
`indirectly in the outcome of this action.
`
`IN WITNESS WHEREOF,
`
`I do
`
`
`
`hereunto set my hand and affix my seal of
`
`office at Chicago, Illinois,
`
`this 9th day of
`
`April, 2018.
`
`Oindbesa & ISO
`
`ANDREA L. KIM, CSR
`
`License No. 84-3722.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 251 of 297
`
`&WNHNF
`oaoOWw
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`INSTRUCTIONS TO WITNESS
`
`Page 252
`
`Please read your deposition over carefully
`
`and make any necessary corrections. You should state
`
`the reason in the appropriate space on the errata
`
`sheet for any corrections that are made.
`
`After doing so, please sign the errata sheet
`
`and date it.
`
`You are signing same subject to the changes
`
`you have noted on the errata sheet, which will be
`
`attached to your deposition.
`
`It is imperative that you return the original
`
`errata sheet to the deposing attorney within thirty
`
`(30) days of receipt of the deposition transcript by
`
`you. If you fail to do so,
`
`the deposition transcript
`
`may be deemed to be accurate and may be used in court.
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`25
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 252 of 297
`
`

`

`nowoF&FWNYOFF
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`L5
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 253
`
`ERRATA
`
`I wish to make the following changes,
`
`for the following reasons:
`
`
`
`PAGE LINE
`
`___-___. CHANGE:
`
`REASON:
`
`___—_—
`
`«___ CHANGE:
`
`REASON:
`
`__
`
`CHANGE:
`
`REASON:
`
`a CHANGE:
`
`REASON:
`
`__
`
`CHANGE:
`
`REASON:
`
`a CHANGE:
`
`REASON:
`
`WITNESS' SIGNATURE
`
`DATE
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 253 of 297
`
`

`

`
`
`2
`
`2 4:16 64:9 128:23
`
`163:10 172:13
`2313312
`25 152:15 153:14
`153:24 154:7,21
`160:18
`
`2.515 36:25 152:25
`20 20:3,5 73:24
`74:3,18 75:2
`83:23 86:19,20
`88:5 95:3 99:14
`99:18,19 118:16
`118:17 119:9,16
`160:4,4 163:15
`176:11 184:15
`200,000 146:19
`147:4,8,11,20
`149:14 152:14
`153:8,11
`2000 162:5 175:9
`176222 211.6
`
`20007 2:21
`
`162:14
`2000s
`175:10,15
`2001
`177:10 217:15
`
`219:15
`
`2002
`161:6 163:19
`176:19 217:13,15
`218:20
`2004 120:4,8
`2006 211:8,11,12
`211:14 212:5,5,8
`212:14 213:4,5,6
`227:13,14
`
`1:26 129:3,5
`
`[& - 2006]
`
`&
`& 2:4,11,19 5:16
`5:19,22
`
`0
`
`01622 23:16 67:11
`
`033 228:3
`
`075 89:17 206:4
`210:21,25 211:12
`211:77,19.21
`212:4 213:7 214:3
`214:12,22.25
`215:4,14,20 216:3
`216:9 217:16
`218:15 219:6,17
`219:25 220:20,24
`22433,11,13,20
`222:4 223:6,14
`DAs 2203
`
`232:22
`
`1
`
`1 4:14 39:4 49:21
`
`50:3 51:12 64:4
`
`67:18 149:16
`190:14,18 244:24
`245:10
`
`1.111 64:25 65:17
`
`1.114 64:20 65:13
`
`1.132 66:14
`1.3 159:10,19
`10 114:10117:15
`
`118:13 119:9
`
`129717 191:20
`
`196:23
`
`100
`
`119:10
`
`1001 42:2 45:6
`1018 205:14,14
`228:6
`1019 205:2,4 206:5
`1025 205:8 219:22
`
`
`
`1055 23:8,14 27:12
`36:3 37:12.33
`39:3 71:2 83:20
`
`112:11 125:25
`129:11 241:8,10
`241:20,22 243:19
`244:3,10,15
`1057 205:19
`229°11,12
`10:52 64:4,7
`11
`113:5,24 138:2
`162:9 17522
`
`137:17 233:11
`1113
`161:14,17
`72513;19 25
`1140
`103:15,16,21
`103:22,24 104:5
`1160
`103:21 104:4
`104:19,21 120:7
`123:19
`1162 64:18 65:11
`66:6,11 67:10,18
`74:25 77:10 82:12
`110:24 111:13,19
`1163 64:23 65:15
`77:9,11,20 80:3
`81:16 82:16 111:6
`
`Liic25
`
`119 72:10
`11:03 64:7,9
`12
`159:25 160:3
`
`16122223525
`236:9,21
`121 239:10
`
`12:35 128:23
`129:3
`
`13 83:20 132:25
`236-82295 2373
`15
`18:6 40:3,8
`41:3 77:25 81:21
`83:14 85:8 160:4
`
`242:2.243:24.25
`152
`149:21
`
`16 77:19 81:17
`
`82:16 83:6 87:8
`96:22 112:11.12
`116:7 156:21
`158:13,23 162:10
`172:24
`
`1621 37:25 241:10
`241:13,22 242:6
`242:19,23 244:4
`244:15 246:9
`
`1622 37:24 39:14
`
`40:8 83:20 110:25
`241:9.21,23,25
`242:18,25
`loa 116:8
`17
`158:13 163:7,8
`172:18
`
`18 43:9 67:2 68:24
`
`70:19 73:24 74:17
`
`78:3 81:22 83:16
`83:23,25 85:9, 11
`86:19 87:21 88:2
`
`88:11 98:14 99:5
`
`100:8
`19 66:10 67:18
`
`70:19 83:23 89:15
`
`190 4:14
`1970s
`162:13
`
`1980 211:2 217:17
`
`218:19
`
`162:14
`1980s
`162:2,15
`1990
`163:11,25 164:7
`174:23 175:14
`
`1990s
`
`161:16
`
`162:14 211:6
`
`227713
`
`1991 220:16
`
`Page |
`
`1994 162:2,16
`163:11,25 164:7
`174:23
`1999 212:16,17,20
`232:23
`
` |
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 254 of 297
`
`

`

`Page 2
`[2007 - 60606]
`
`
`2007 235:11
`
`2a7 21
`2009 26:9,16 27:15
`73°77 116:20,35
`120°2.1.1) 15204
`160:19 183:13
`
`224:20
`2010
`116:9,21,22
`120:2 176:3
`
`22175 22325
`224:16,19 225:20
`226:10 227:2,6,18
`228:2 232:25
`
`23355
`23 74:25 77:9,11
`149:20 151:22
`
`152:10 161:3
`
`247:10
`
`224:20 231:25
`
`234 4:17
`
`2010s 224:21
`
`24 43:9 45:16
`
`2013 27:21 28:3
`
`142:6 151:24
`
`TT
`
`2014 27:21 28:3
`
`Te
`
`2015 142:11
`
`184:21
`2016
`142:12,12
`152:25 160:19
`
`184:21
`
`2017
`
`19:23 24:7
`
`25:16 34:4 39:6
`
`39:21 40:21
`
`142:12 184:22
`
`2017-01621
`
`1:6
`
`18:25 23:15 39:4
`45:6 65:11,15
`2017-01622 1:7
`
`18:24 23:9 42:2
`64:19,23
`2017-10621 37:12
`
`152:7 158:20
`160:2 247:9,10
`240 4:6 36:18
`37:13,18 39:17
`40:16 41:4,6
`45:19 47:22 48:9
`48:14 49:3,16
`50:9,18 51:24
`53:2 54:2,14
`55:10 58:9,12
`59:14 65:14,18
`210521 211-722
`212:18,25 213:9
`214:4 227:19
`246:8,21 247:17
`243 4:18
`
`244 4:7
`246 4:8,9
`25 4:24 24:3 39:4
`
`2018 1:20 5:7 34:2
`
`39:16 244:24
`
`249:21 251:10
`
`245:7 247:10
`
`21 24:6 39:20
`
`26 25:10 66:19
`
`83:23 87:21 89:18
`2A2
`°226:1.1 238°?
`
`228:11
`
`22 66:9 67:2 68:22
`
`24717
`
`222 89:17 204:7
`218:15 220-15,24
`
`77:20 81:16 84:4
`87:21 241:19
`244:7,8
`27 8922 21072
`
`28 89:24 210:24
`
`3
`
`3 4:17 129:5
`
`138:24 191:6
`
`193:19 194:3
`204:15 234:21,25
`236:8 243:4
`
`3.5
`
`159:11
`
`3.565
`
`158:24
`
`30
`
`176:11 252:14
`
`3000 2:20
`
`31
`
`90:3
`
`32, 27:20
`
`325
`
`149:10
`
`146:14
`33
`333 226:11
`34 27:11,19
`35
`1:18 2:5 90:8
`
`99:14 100:23
`
`218:8
`
`36 99:15
`37 64:20,25 65:13
`65:17 66:13 84:4
`
`87:21 90:9 99:15
`106:5.6
`38 36:2.152:22
`3:03 204:15,18
`3:13 204:18,20
`4
`
`4 4:1,18 36:4 71:3
`71:15 73226
`141:22.152:21
`204:20 243:4,12
`243:17,25 244:7,9
`244:14 246:6,7,19
`246:20 248:4
`4,306,075 205:3
`4/6/18 190:15
`
`231:9 234:22
`
`243:13
`
`
`
`
`
`
`
`40 8:2
`
`439 72:11
`
`45
`152:22 241:20
`244:7,8 245:2,3,10
`245:10
`
`470 149:21
`
`4800 1:18
`4:01 240:2,4
`4:10 240:4,6
`4:18 248:4,8
`
`5
`
`5 80:2 137:8 138:3
`
`141:12
`5,153,222 205:9
`219:23
`
`MM 7:29 S112 16:13
`507 23:17 36:3,18
`41:5 44:4,7 45:15
`45:23 47:21 48:9
`48:14 49:3,17
`50:9,17 51:24
`52:25 $4:2,15
`55:11 58:9,13
`59:14 64:21,25
`Tid 12535
`
`129:12 210:22
`211:7,21 212:18
`212:25.213:9
`
`214:4 227:18
`
`540 45:21
`
`6
`
`6 4:5 5:7 40:14
`
`242:19
`6,521,212 205:15
`228:6
`6,756,033 205:21
`229:11
`
`600 2:20
`
`60606 2:6
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www. veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 255 of 297
`
`

`

`[6th - agree]
`Page 3
`
`
`6th=1:19 am. 1:205:8 64:4|acoustical 50:4 administering
`
`
`"
`64:7,7,9
`51:12,15
`62:19 236:3
`
`leavacme.re|ability 137211 action 107:3 administration
`
`
`55:16 105:24
`138:18 139:13,14
`127:13
`2 en able
`25155 an a 11077
`119-9
`ead 221:14
`220;12
`advanced 28:17
`_ ie. 239:11
`abridged 246:13
`activities 208:21
`134:3,10
`78746-5546 2:14
`absence 41:2
`pS 246:7,19 actual 155:9161:9|advantage 120:18
`
`
`8
`_ abstract 194:8
`162:4,9,20,22
`120:23 121:24
`8 41:12 66:18
`232:4 235:16
`163:22 164:6,15
`122:10
`119:25 126:3
`academic 8:23
`175:6,8 186:17
`advantages 81:4
`129:12 132:24
`178:9,11,11
`187:11,22
`95:6 98:15 120:25
`
`
`134:8 135:13 acceptable 236:7=adcirea 126:13 121:3,4
`[36:21 137:3,4
`accepting 178:2
`137:4,8,15
`adverse 80:6
`
`8,410,121 4:17 add 117:25119:2|affect 7:20 55:20accepts 179:11
`
`
`235:2
`access 240:14,18
`addition 22:10
`144:8,25 197:15
`80 8:12 20:4,5
`240:24
`83:24
`affirmed 250:12
`127:5
`72:9,12 157:8
`account
`additional 8:3
`affix 251:8
`84-3722 1:18 3:22
`131:8 137:14
`89:4 121:17
`aforesaid 250:11
`250:8 251:14
`140:3 152:9
`159:12 246:6
`250:19
`9
`189:11
`address 84:24
`agent 236:15,23
`9 41-12 241-18
`_accounting 189:21
`85:18 86:25 87:15
`ago 38:11 162:10
`
`
`
`
`
`c
`
`9,339,507 42:6
`9,358,240 45:7
`9,550,716 231:13
`9,550.716..231
`4:16
`
`90 77:25 81:21
`
`83:14 85:8 118:2
`119:3,13 156:25
`900 2:12
`
`90s 227:10
`
`9:35 5:8
`
`9:37 1:20
`
`9th 251:9
`
`| a.d.
`
`a
`1:20
`
`accumulated
`26:25
`accurate 23:24
`29:13. 37:18
`
`105:21 162:12
`250:18 252:16
`accurately 156:4
`accused 9:7
`
`achieve 127:13
`La i2,8
`achieved 13:17
`33:15 142:10
`
`187:16
`achieving 13:21
`LY7318 148222
`acknowledges
`116:3;5
`
`
`
`active
`
`137:
`
`3:
`
`100:9 101:9
`addressed 44:10
`44:18 84:21 152:6
`addresses 43:14
`
`98:23 101:11
`178:12
`addressing 87:22
`124:21
`129:18
`adempas
`130:9,23 132:16
`133:3,5
`administer 53:24
`§5:9,24 56:10
`228:14 229:15,23
`administered
`
`61:21 75:5 101:19
`106:21
`
`12:5 14:19
`agree
`33:4 34:14 41:20
`44:12 46:5,11,14
`48:12 49:2 57:13
`
`58:22 60:2 68:4
`68:17 73:6,14
`75:9 76:16 83:9
`85:4,23 86:6,14
`87:13 92:14 94:18
`98:6,12 99:3,13
`104:16,18 105:10
`110:9 111:18
`
`112:8 119:16
`
`121:19 122:25
`
`123:5 13.1512
`
`133:15 140:22
`141:10 142:5
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 256 of 297
`
`

`

`Page 4
`[agree - area]
`
`
`149:12 150:25
`12:21 154:13,19
`164:5,13,25 165:4
`169:14 180:10
`
`181:25 186:16
`
`187:9 189:17
`190:2,4,7 191:15
`192:7,22, 19391
`194:9,21 197:9
`201:9 207:24
`208:15,25 211:20
`212:3,4 213:14,22
`217:9 219:16
`2221222 223713
`238:9,25 247:6
`agreement 75:11
`agrees
`178:20
`ahead 22:4
`allege 38:14
`alleged 49:12
`55:15 74:17 78:19
`
`80:23 83:21 84:3
`98:2,14 99:22
`100:3,20,25
`238:20
`
`134:20
`alleviate
`allow 158:17
`
`238:16
`
`allows 29:8 110:6
`2225
`
`alternative 56:17
`
`S711 7023: 72:19
`
`amendment 64:24
`
`65:16
`
`amount 158:5
`183:18 222:7
`
`amounts 236:5
`analog 105:4
`analogs
`102:5
`105:8
`
`analyses 48:4
`158:8
`10:9,9
`analysis
`11:3,5 26:23 33:9
`34:4,5,5 42:14
`43:13,14 44:16,20
`45:16,24 46:8
`47:9 48:10 71:10
`71:19,21,22 81:4
`96:24,25 97:12
`101:21 113:25
`
`131:10 139:22
`
`140:15 141:7
`
`142:2 143:24
`144:3,6 145:24
`I5T15 1529
`153717 1562.13
`157:16 159:19
`161:4,7,8 166:16
`166:24 168:17
`
`169:2 173:23
`
`177213 178:21
`
`179:6 183:3 187:4
`191:17 192:17,24
`193:5 197:25
`198:5,24 200:9
`201:22 203:14,20
`207:16 214:17
`225:14,15 230:18
`240:14
`analyze 43:12
`150:2,4 161:2
`LO: 10, 1 72:2
`
`184:10 189:25
`
`195:3 196:2
`analyzed 31:6
`33:22 36:21
`
`153:20 154:16
`
`155:18.159:21
`167:9,14,15 172:5
`176:7 198:3
`
`
`
`
`
`199:22 239:20
`analyzes
`161:25
`analyzing 30:15
`140:4 160:23
`166:10 169:5,16
`193:22
`
`andrea 1:16 3:21
`
`5:11 250:6:251:13
`
`annual
`
`142:25
`
`145:14 149:20
`
`158:23 161:4
`
`answer 6:25 7:9
`19:9,14,14,18
`29:13 52:5 79:8,9
`100:15 137:17
`
`153:18 154:3
`
`181:12
`
`answered 87:17
`94:20 97:3,19
`108:4 213:12
`
`answers 7:16 9:5
`
`19:11 66:4 155:16
`antagonist 138:13
`anticoagulants
`113:9
`anybody 212:22
`apologies
`144:21
`apologize 91:3
`apparently 218:19
`appeal
`1:3
`appear 66:24 70:6
`72:6 T7:15 79:22
`
`$1:6 82:13 95:7
`
`106:3 175:12
`appeared 2:2,10
`appears 23:22
`24:2 40:3 42:8
`
`69:7 76:16 80:14
`
`82:10 104:24
`
`105:21 116:19
`118:8 119:19
`
`134:8 158:14
`
`236:22 241:18
`apples 35:18,18,21
`3521
`applicability
`127:11
`19:19
`applicable
`34:5 114:3 176:4
`application 101:5
`218:12
`applications 213:4
`applied 28:21
`applies 46:8,12
`186:22 224:4
`apply 30:4 153:19
`186:21 200:18
`
`201:6
`apportionment
`10:7,10,24,25 11:2
`P1213,19
`appropriate 10:13
`128:12 140:6,19
`140:23 141:4
`
`165:2 166:14
`
`120:8
`
`171:2 174:2 252:5
`appropriately
`48:10
`approval
`147:25
`approved 80:9
`105:12 114:5
`116:4 120:4,10
`134:8 138:4 157:2
`
`157:8
`approximately 5:7
`7:22 19:24 21:13
`
`147:14 149:10
`april
`1:20 5:7
`251:10
`
`area 31:19 34:24
`109:3
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www. veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 257 of 297
`
`

`

`[arterial - back]
`Page 5
`
`arterial 36:12
`100:21 102:18
`245:5,11 246:12
`averages
`150:6
`105:17 114:5,14
`108:7,22 111:21
`247:7,10,16
`159:7
`114:20,22 115:4,7
`227:21 230:10
`attempt
`135:7
`aware 40:24 41:7
`123:13,24,25
`aspire 80:5
`132:3 155:20
`49:14 50:7 52:23
`126:25 128:9
`asserted 226:14
`166:22
`53:22,24 54:8
`
`
`130:3 134:19 assessment 84:12|attend 29:2 59:12 61:8,18,24
`135:18 137:10
`144:20
`attorney 32:3
`62:8,18 63:6
`139:7 157:22
`assigned 235:5
`250:24 251:2
`103:4 109:24
`158:4,10 159:22
`assignee 206:13
`252313
`122:7 124:12
`177:9,15 232:20
`133517 135:11,68
`231221
`attributable 57:16
`assignees 220:25
`140:2 155:3,7,19
`article 4:14 161:6
`157:25 160:10,15
`assist 21:12 42:19
`166:18 169:23,25
`assistance 245:18
`assistant 24:10
`170:7 176:20,24
`assisted 20:20
`177:20,23 179:17
`24:18
`188:15 196:6
`associated 43:7
`201:18 223:18,20
`115311 1212
`231:4 244:12
`124:2,10 189:22
`b
`192:3 193:11
`
`10:21 25:4
`
`161:14 172:13
`193:19
`articles
`25:7
`articulated 85:16
`178:8
`arts 25:24
`asked 13:5 45:15
`87:17 90:17 94:20
`
`58:12 76:18 86:22
`
`attributes 81:8
`128:6 203:4
`230:10
`austin 2:14
`author 190:23
`authors 175:24,25
`176:18 190:25
`191:5
`availability
`
`
`
`
`
`
`
`:
`
`:
`
`b a oe a
`201-22 202:9.11
`196:25 230:9
`97:3,19 104:9
`1263 129:12
`202:22,24 203:6
`assume 66:4 91:21
`108:4 113:19
`131-24 132-24
`available 53:9
`91:21 122:17
`203:24 209:12
`134:8 135-13
`56:8,10 61:10
`assuming 58:8
`213:12 246:18
`13621 1373
`195:3.7,12.17,19
`Z212:17 225:20
`asking 33:19
`158:2 160:11,15
`239:10
`69:14 90:12 96:7
`141:12,22 152:21
`
`100:5,18 108:23|assumption 160:21 161:2
`
`166:18 170:11 oa
`225:25
`113:23 134:18
`177:9 188:18,20
`hachelar’s. 21:92
`attached 68:4
`139:9 143:9
`188:23 196:13,14
`95-19.20.24
`126:2 249:12
`182:11 215:12
`
`
`aspect 9:22 26:22 197:8.198:19.20|oy 44-6 7.43:8252:11
`5§7:24,25 95:20
`attachment 36:4
`198:21 199:21,24
`61:7 64:10.12
`
`aspects 26:2431:6|37:7,22 38:3 71:3 200:3 203:8,11 75-93 101-21
`
`42:20 47:5,24
`71:15 73:2,5
`206:18 217:10
`106-5 112:10
`
`78:20 80:23 84:20|126:3 129:12 218:20 227:8 113-4 115-13
`
`87:25 88:7,18
`134:8 135:13
`average 34:14,19
`116-7 129-6.8
`89:7,16 90:19,20
`137:3 141:12,18
`35:2 149:22
`137-25 147-12.17
`90:24 91:2,5,8
`141:21,22 152:21
`156:20 158:25
`149-8 155-23
`
`92:25 93:4,12,18|attachments 38:5 159:16,18 161:6 161°3 172-12
`
`
`
`93:22.24 94:3 39:12,24 40:17,22|173:3 174:13,16 184-25 195-16
`97:9 99:22 100:3
`41-3 241:19,23
`204:21 214:8
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 258 of 297
`
`

`

`Page 6
`[back - bullet]
`
`
`240:6,7
`background 21:21
`25°18:52:22
`
`bad 146:7
`ballpark 8:12,15
`20:7
`bargaining
`10:16
`
`10:16
`
`base
`
`172:21
`
`based 10:10 19:10
`57:17 58:4,5 60:9
`63:10 68:19 70:22
`70:24 72:16,19
`74:3 76:16 79:23
`80:14 82:21,25
`83:22 88:21 107:2
`107:3 114:4,4
`140:18,21,25
`142:3,12 143:20
`143:24 145:10
`
`behalf 2:2,10 5:19
`5:22 18:22
`
`believe
`19:22
`22:14 24:12,24
`29:97 3010.17
`35:24 37:8 44:9
`
`44:14 49:8 54:5
`54:19,25 62:4
`67:8 70:20 94:9
`
`97:17 116:24
`147:16,21 148:5,7
`148:14 155:6
`162:11 170:3.13
`L7ES 17733 1786
`
`180:20 186:2
`
`211°5 212°16
`215:°10.25 217:6
`217:12 225:24
`
`231:15 235:4
`
`241:12
`
`146:7 147:7
`
`162:12 163:22
`164:12 175:6,11
`181:9 184:14
`
`benchmark 173:9
`173213,19 174:2.7
`174:20
`
`benchmarks
`
`186:25 187:21
`
`155725 156:6
`
`188:4 199:4
`215223 216;10,20
`DEF 220e7
`2271922
`basically 121:7
`basis 79:3 80:16
`135:5,16 143:6
`157:16 168:17,17
`169:21 170:24
`
`176:9 197:7
`bdelafield 2:16
`becoming 145:17
`began 212:25
`beginning 64:9
`129:5 204:20
`
`benefit 74:14
`101:4 122:2
`
`218:10
`
`benefits 43:7
`56:16 57:4,11
`73:20 74:18,23
`85:13,17,19 88:3,6
`200:11,24
`best 7:16 19:12,18
`73:17 102:2 149:7
`Les 21720
`
`218:8 224:22
`
`better 94:10 123:6
`
`139:11
`beyond
`185:10
`
`175:3,4
`
` big 222:23
`
`billion 36:25
`152:395,25: 153314
`153:24 154:8,22
`158:24 159:10,11
`159:20 160:18
`
`billions
`
`150:20
`
`biochemical 138:5
`
`140:12
`
`bit
`
`118:17
`
`block 210:8 221:4
`
`221:7 226:15
`
`blockbuster
`
`151:3
`
`blocked 210:4
`221318,25 223:5
`225'2 29620
`230:16,24 232:9
`238:10 239:14
`
`blockers
`113:10
`blocking 89:23,24
`93:20 204:8
`207:12,195,21
`208:2,4,7,15,20,25
`209:13,15,21,23
`210:13.21 20-1;11
`211:13,15,16,23
`212:4 213:8,18,23
`214:3,13,14,18
`215:2,6 216:6
`219:8,10,17,19
`WAT 225)LAS
`22073 2271825
`290213 232:16
`238:18,22
`blocks 207:17
`208:8,20 209:2
`blood 107:3
`
`bloodstream
`
`LOF17
`
`board 1:3
`
` bobby 2:15 5:15
`
`38:7
`body 108:9,12
`book 36:19 48:23
`
`49:10 55:13 176:2
`
`220:11 224:20
`
`226:12 228:4
`
`boston 40:19
`
`bottom 244:23
`
`brand 16:21
`
`144:15
`
`branded 32:21
`break 7:12,14
`63:25 128:16,21
`152:19 174:13
`
`204:12 239:23
`
`breakdown 43:16
`
`44:20 168:3
`
`breaths 78:3 81:23
`
`83:16 85:9 87:9
`
`87:16 88:10 99:7
`99:9,20,25 100:10
`101:12,19 111:7
`brennan 20:16,19
`21:15 24:18 25:9
`
`brennan's 21:20
`brief 232:18
`briefly 25:17
`66:17
`bring
`195:7
`bringing 210:8
`22110
`
`[91:12
`
`broader 70:12
`
`127:12 128:7
`222:24
`broadly 102:19
`brought 194:5
`221125
`
`bullet
`
`129:19
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 259 of 297
`
`

`

`[burroughs- cited]
`Page 7
`
`
` charts 247:7,8,12
`
`cheating 8:23 9:8
`check 147:12
`
`188:17
`
`checked 71:9
`checking 188:22
`chemical 58:3
`
`chemist 215:17
`chemistry 215:19
`220:3
`chicago 1:19 2:6
`40:19 251:9
`
`choice
`
`135:21
`
`chose 162:20
`
`chronic
`129:20
`150:10:27 132-21
`cimas 2:13
`circulating 107:2
`circulatory 106:14
`108:3
`
`circumstance
`
`166:5 189:10
`
`190:11 193:25
`
`197:13 226:25
`
`circumstances
`
`136:15 143:18
`166:5 185:22
`
`201:12 207:10
`
`citations 87:20
`180:6
`
`cite 25:4 43:6
`
`139:3 161:22
`
`163:7 172:9
`179:13,14,19,23
`191:21 192:15,18
`247:3
`
`cited 40:13 164:18
`
`175:25 176:15
`
`179:21 180:4
`
`182:9 203:21
`220:19 242:19
`
`
`
`
`
`11:6,8 13:12,25
`14:10 15:15 19:4
`20:27 2213. 16.15
`27:5,10.13 28:2
`3h 33410 35°16
`44:4,23 45:19
`59:15 6fi1l 76:6
`
`83:20 90:19 94:4
`
`95:21 108:14
`110:24 122:5,5
`135:4,4 143:7,21
`153:17, 1025
`154:9 157:16,16
`170:24,24 172:3,3
`183:9 186:5
`
`195:25 196:17
`
`197:14 201:16
`
`204:9 239:21
`240:14,24 241:9
`24111132122
`241:24,25 242:6
`242:23,25 246:9
`cases 8:3,7,10,13
`8:14 12:12 14:20
`15:6 16:3,14,20
`17:6,16,17 18:22
`19:11,15,19,21,25
`20:12 21:4 27:18
`
`27:23 29:9 30:5
`33:12 66:6 67:12
`
`103:17 104:21
`
`161:17 168:16
`185:18 205:4,9,14
`205:20 228:8
`
`229:12 241:2
`ceo
`116:8
`
`certain 11:17 12:4
`
`13:9 14:17 20:25
`
`49:21 50:4 51:11
`86:9,11 87:25
`121:24 126:18,21
`
`135:2,3 136:14,14
`190:12 224:2,4
`230:9,10 231:6
`234:19 243:10
`certainly 27:5
`28:16 29:6 30:2
`
`69:22 167:13
`185:13,16 196:21
`226:10 227:9
`
`certificate 250:2
`
`certified 1:17
`250:4,7
`certify 249:10
`250:8
`
`cfr 64:25 65:17
`challenge 121:21
`224:13
`challenged 9:20
`10:19
`change 47:8 109:6
`109:20 110:12
`187:18,25 199:19
`246:7,20 253:9,11
`292013,13,17,19
`changed 175:14
`176:11 177:4
`changes 252:9
`25355
`
`113:10
`channel
`176:3
`chapter
`characterization
`
`207225
`
`characterize
`
`182:16
`chart 40:4,7,10
`98:8 156:21
`
`158:22 164:6
`241:17 242:2,5,9
`242:13,17 244:2
`246:12,25
`
`burroughs 221:4
`221:14,25 223:14
`c
`
`c 83:21 90:10
`
`cfr. 64:20 65:13
`
`66:13
`
`calcium 113:9
`
`calculate 37:4
`
`70:23
`
`calculated 34:23
`
`35:24 69:10 158:3
`
`173:24
`
`calculation 72:8
`
`calculations 21:10
`21:14,16,18 37:23
`58:35 17221522
`247114721
`calibration 10:15
`
`california 67:21
`
`call
`
`116:9 121:16
`
`122715
`
`called 1:12 6:6
`
`10:9 67:3
`cancer 150:18,20
`capable 207:2,4
`capacity 129:22
`130:4
`capital 2:12
`189:21 192:2
`
`193:10
`capitalization
`183:8,12,16,22,23
`184:5
`156:5
`captures
`car 59:24 60:4,9
`60:12,14,16,17,24
`care 67:24 148:15
`
`171:5
`career
`carefully 252:3
`case 4:19 8:18 9:2
`9:17,25 10:12
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 260 of 297
`
`

`

`Page 8
`[cites - common]
`
`
`cites 41:4
`
`civil 1:14
`
`claim 31:20 43:16
`
`43:19 44:16 46:7
`
`47:7:50:3. 51:12
`
`class 30:6 105:19
`
`LES5:10 123923
`124:7,16,24 125:5
`123:6,12 126:7,11
`126:14 129:23
`
`63:15 69:7 70:8
`
`130:5 133:9
`
`136:22 138:16
`
`classes
`
`124:13
`
`125:17 134:9
`
`137721 139:17
`
`clear 38:19 52:7
`
`69:18 77:22 81:18
`
`82:11 83:13 84:9
`84:12,25 86:9,11
`87:2,25 101:10
`228:14 229:14
`235:25 236:8,9,25
`237:8
`claimed 42:13,23
`43:7 49:16 52:20
`55:7,10 73:25
`81:9 82:4 84:6
`85:13,16,19 87:23
`88:3,7,18 90:7
`91:6,13 94:6
`207:19 208:10
`
`101:23 169:4
`P7isS
`
`
`
`152:12 226:13
`clearly 95:10
`clinical 31:5,23
`51:17 57:4,25
`63:23 68:13 73:19
`74:14,23 75:16
`commercial 4:15
`12:16,21,25 13:15
`76:22 81:4,11
`13:17,21,25 14:6
`87:25 88:3,6
`14:15,22 15:3,9,16
`92:20,21 95:6
`209:5 230:21
`claiming 215:14
`15:19 16:4 17:12
`97:9 98:14 100:23
`17:14,19,21 30:15
`100:24 101:3,17
`216:5 236:14
`33:5,9,15,23 34:16
`claims 43:9,12,15
`102:18 103:5
`35:5,11 47:4
`107:7 108:18,22
`44:3,6,10,13,19,21
`130:5 139:10,11
`44:21,23 45:18,24
`238:19
`53:10 55:21 56:9
`commercialize
`58:7,11 59:9,24
`148:2,18 218:10
`46:5,8,9,12,16,18
`22013 23958
`67:3 68:23 76:24
`224:8
`47:21,22 48:13
`commercialized
`TZ ek TS22
`Clinically 69:2
`49:3,21 51:10
`217:18
`80:22 81:6,18
`81:3
`54:14 55:17,20
`
`61:21 62:15 63:11|clinician 50:11 82:6 83:21 84:3,5|commercializing
`63:20 77:24 81:20
`96:14 102:7,12,14
`84:19 85:20 86:12
`225:10
`84:20 86:4 87:8
`138:15
`86:21 87:3,10,23
`commercially 13:6
`102:21
`90:14 95:13 98:3
`clinicians
`88:12,19 89:8
`13:10 14:11,14
`2276 235:24
`closer
`159:16
`90:21 91:14,16
`60:16 61:10
`2:36:21 238:7
`collection 211:15
`92:12,16 93:4,13
`173:10,13,19
`clarify 33:18
`collectively 43:15
`95:12.98:3 111:22
`174:15 177:8
`44:11,19 46:6
`44:22 72:21 93:23
`127:3 143:14
`217:10 218:20
`college 25:21
`colleges 29:2
`
`
`
`column 43:9
`
`135:12
`
`combination
`
`162:22 164:16
`
`2372-23812
`
`combined 162:16
`
`come 17:9 117:17
`118:13,18,21
`145:4
`
`comes 27:19 30:7
`
`31:18 41:15 59:2
`
`O14 Tet 1F
`144:16,17 145:7
`218:10
`coming 145:16
`commencement
`
`250:10
`
`145:25 146:18
`147:7 148:8,16,25
`152:16 153:13,21
`
`153:25 154:6,9,17
`156:2 157:2,9,13
`157:18 160:24
`164:24 165:6,15
`166:2 169:6,17
`170:18 171:6,17
`172:2 174:2,12,20
`180:14 181:3,8,17
`183:24 184:7
`185:19 186:8,24
`189:7,18 190:9,20
`191:8,17,24
`192:13,17,23
`193:4,7,23 194:13
`194:22 195:10,13
`195:15,22 197:10
`197:16,21,25
`199:17 200:8,10
`201:10 202:12,20
`203:18,25 217:24
`218:21 219:3,7
`234:2,7,11 238:20
`commercialization
`
`189:23 192:4
`
`193:12 208:21
`
`219:12
`
`common 51:6
`165:16
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www. veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 261 of 297
`
`

`

`Page 9
`[commonly - context]
`
`commonly 102:25
`117:20 118:23
`companies 73:4
`90:6 166:19
`
`
`
`200:9,10 201:21
`202:15 214:18,25
`consideration 14:6
`14:22 15:4,8,8,20
`15:22 16:4 17:15
`
`17:22 186:25
`
`190:6 203:17
`
`considerations
`203:22,23
`considered 28:8
`
`156:23 189:18
`
`190:9 191:23
`
`201:25
`considering 32:17
`34:18,21 35:9,23
`38:16 59:24
`
`181:21 196:8
`
`199:20 210:6
`
`consistent 85:15
`
`95:4 107:19 125:2
`
`128:12 140:6
`160:5 171:23,24
`194:11 218:25
`consistently
`245:10
`
`constitutes 250:17
`consultant 27:3,23
`30:23
`
`consultation 32:15
`consulted 32:7,24
`consulting 17:16
`28:6 80:3
`
`contain 40:17
`contemplating
`212:9
`content
`
`10:9
`
`contents 241:6
`
`context
`
`10:12
`
`11:20 28:16 30:10
`
`30:12